Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

The cryptocurrency market is shifting, and while AI cryptos have captured attention, other groundbreaking projects are ...

If visual content helps brands in all these ways, surely more of it is better, right? In theory, yes, but in practice, not ...

Clays, the British experiential clay shooting bar brand, has just announced a significant US expansion alongside its largest ...

We view shareholder distributions as appropriate. Historically, the dividend payout ratio has been around 50% of net income. 2024 dividend payments totaled EUR 2.25 per share. BASF plans to continue ...

The manufacturing sector is undergoing a seismic shift as companies race to embrace digital technologies in an increasingly ...

Their success directly challenges three deeply entrenched beliefs that have dominated AI development for years. The first is ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

“The now-confirmed and rumored additional cuts to come at NOAA/NWS are spectacularly short-sighted, and ultimately will deal ...

Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in ...